“Palonosetron Hydrochloride Injection” Passes Consistency Evaluation

Release time:2021-05-13

Recently, “Palonosetron Hydrochloride Injection” (Product name “Zhiruo”) (specifications: 5ml: 0.25mg and 1.5ml: 0.075mg), a drug developed by the Group, for the prevention of nausea and vomiting caused by chemotherapy has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.

Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist with a highly selective antagonistic effect on 5-HT3 receptors, reducing the incidence of nausea and vomiting, and is currently the only 5-HT3 receptor antagonist approved for the prevention of late-onset malignant vomiting. Compared with other 5-HT3 antagonists, palonosetron hydrochloride has the advantage of a long halflife and strong affinity to the receptor. With its good efficacy and safety, palonosetron hydrochloride has become a common drug for clinical prevention of chemotherapy-induced nausea and vomiting.